Highest-materiality recent filing
Apogee secures up to $1.3B non-dilutive financing from Blackstone for zumilokibart
$100M upfront received; additional $100M upon Phase 3 enrollment, $200M on positive Phase 3 data.
Primary endpoint met: 65.9% mid-dose EASI-75 (p<0.001 vs placebo 23.4%) at 16 weeks.
Apogee reports Q1 loss of $74.1M; $1.3B cash; zumilokibart Phase 3 AD on track
Net loss of $74.1M in Q1 2026 vs. $55.3M a year ago; R&D spend $60.8M, G&A $22.0M.
Apogee Therapeutics prices public offering of 5M shares at $70, net ~$377.4M
5,000,000 shares offered at $70 per share; underwriters' option for 750,000 shares exercised in full.
EASI-75 maintained in 75% (3-month) and 85% (6-month) of Week 16 responders; vIGA 0/1 maintained in 86% and 78%.
Zumilokibart showed maximum mean FeNO reduction of 45 ppb (60% decrease) after single 720 mg dose; suppression durable through 16 weeks in all patients and up to 32 weeks in some.
Q3 2025 net loss $65.0M vs $49.0M YoY; cash and securities $588.9M pre-offering, $913M pro forma post-$345M equity offering.
Apogee (APGE) raises $323M, updates APG777 atopic dermatitis and asthma trials
Offering of 6.95M shares at $41 plus pre-funded warrants and full underwriter option exercise, net proceeds ~$323.3M.
Apogee reports positive APG777 Phase 2 data and Q2 net loss of $66.1M
APG777 APEX Part A met primary endpoint: 71.0% EASI reduction vs 33.8% placebo (p<0.001).
Apogee: Phase 2 APG777 hits all endpoints; EASI-75 66.9% (42.5% placebo-adjusted), safety favorable
APEX Part A met primary endpoint: 71% mean EASI reduction vs 33.8% placebo (p<0.001).
Apogee reports Q1 net loss $55.3M; positive APG808 Phase 1b data with 53% FeNO suppression
Q1 net loss $55.3M vs $32.1M YoY; cash $681.4M supports runway into Q1 2028.
Apogee Therapeutics enters manufacturing agreement with Samsung Biologics for APG777 drug substance
Master Services Agreement with Samsung Biologics for manufacture and supply of APG777 drug substance for clinical development and commercial sale if approved.
Apogee reports positive interim Phase 1 APG990 data with ~60-day half-life; 2024 net loss $182.1M
APG990 demonstrated ~60-day half-life, supporting every 3- and 6-month maintenance dosing; well tolerated up to 1,200 mg.
Apogee doses first patient in Part B of Phase 2 APEX trial for APG777 in atopic dermatitis
Part A enrolled 123 patients (exceeded ~110 target) randomized 2:1 APG777 vs placebo; >90% power for primary endpoint.
Apogee doses first healthy volunteers in Phase 1 trial of TSLP antibody APG333
APG333 is a novel half-life extended monoclonal antibody targeting TSLP for asthma, COPD, and I&I conditions.
APG808 interim Phase 1: half-life ~55 days, supports every 2-3 month dosing; well-tolerated; Phase 1b in asthma expected 1H 2025.
Apogee Therapeutics Reports Q3 2024 Financial Results and Pipeline Progress
Cash, cash equivalents and marketable securities of $753.8M as of Sept 30, 2024, with runway into 2028.
Apogee reports positive Phase 1 APG777 data: half-life ~75 days, sustained PD effect up to 9 months
APG777 half-life of ~75 days is about 3–5× longer than currently approved moderate-to-severe AD treatments.
Initiated dosing in Phase 1 trial of APG990, a half-life extended OX40L antibody, enrolling ~40 healthy volunteers in 5 cohorts.
Apogee reports Q2 net loss $33.8M; cash $789.6M; APG777 Phase 2 dosing started
Q2 2024 net loss $33.8M ($18.9M in Q2 2023); R&D expenses $33.2M, up from $13.9M.
Apogee starts Phase 2 AD trial for APG777; Phase 1 shows ~75-day half-life
Initiated dosing in Phase 2 trial of APG777 for moderate-to-severe atopic dermatitis (AD).
Net loss $32.1M vs $12.5M YoY; R&D expenses $28.7M (up from $8.5M) as pipeline progresses.
the board of directors (the “Board”) of Apogee Therapeutics, Inc. (the “Company”) elected Lisa L. Bollinger, M.D. to serve as a Class II director of the Company
Max materiality 0.90 · Median 0.70 · Most common event other_material